Galectin Therapeutics (GALT) Treasury Shares (2010 - 2026)

Galectin Therapeutics has reported Treasury Shares for 17 years, with the latest figure at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares fell 56.52% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (down 56.52% YoY), and the FY2025 full-year result was $4.2 million, down 56.52% from the prior year.
• Treasury Shares for Q1 2026 stood at $4.2 million, roughly flat from $4.2 million in the prior quarter.
• The five-year high for Treasury Shares was $12.0 million in Q2 2023, with the low at $4.0 million in Q3 2025.
• Average Treasury Shares over 5 years is $9.2 million, with a median of $9.6 million recorded in 2024.
• Year-over-year, Treasury Shares climbed 10.13% in 2023 and tumbled 58.72% in 2025.
• Tracing GALT's Treasury Shares over 5 years: stood at $11.6 million in 2022, then retreated by 19.91% to $9.3 million in 2023, then climbed by 3.67% to $9.6 million in 2024, then slumped by 56.52% to $4.2 million in 2025, then changed by 0.0% to $4.2 million in 2026.
• The last three Treasury Shares figures came in at $4.2 million (Q1 2026), $4.2 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.

Peer Comparison